Literature DB >> 21406499

Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot study.

Christian H Roux1, Veronique Breuil, Laure Valerio, Nicolas Amoretti, Olivier Brocq, Christine Albert, Christian Grisot, Yacine Allam, Patrick Chevalier, Christian Pradier, Lianna Euller-Ziegler.   

Abstract

OBJECTIVE: To compare etanercept (anti-tumor necrosis factor-α) with intraarticular (IA) corticosteroid injections to treat rheumatoid arthritis (RA).
METHODS: Patients with RA who had persistent monoarthritis received etanercept or IA corticosteroid injections. Efficacy was compared at Weeks 4 and 24.
RESULTS: Thirty-four patients were included (8 dropped out). Mean age was 58.8 years. No difference between groups was found at Weeks 4 or 24, but both groups showed significant improvement at Weeks 4 and 24 compared to baseline.
CONCLUSION: Etanercept and IA steroid injections resulted in significant improvement at Week 4 that persisted to Week 24. There was no significant difference in outcome between the groups.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21406499     DOI: 10.3899/jrheum.100828

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis.

Authors:  K A Kimmerling; B D Furman; D S Mangiapani; M A Moverman; S M Sinclair; J L Huebner; A Chilkoti; V B Kraus; L A Setton; F Guilak; S A Olson
Journal:  Eur Cell Mater       Date:  2015-01-31       Impact factor: 3.942

2.  Comparison of the effectiveness on intra-articular and subcutaneous TNF inhibitor in rheumatoid arthritis patients.

Authors:  Fangze Zhang; Cuili Ma
Journal:  Clin Rheumatol       Date:  2017-09-04       Impact factor: 2.980

3.  Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare.

Authors:  Francesco Carubbi; Luigi Zugaro; Paola Cipriani; Armando Conchiglia; Lorenzo Gregori; Cristino Danniballe; Maria Letizia Pistoia; Vasiliki Liakouli; Piero Ruscitti; Francesco Ciccia; Giovanni Triolo; Carlo Masciocchi; Roberto Giacomelli
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

Review 4.  Role of ultrasound in managing rheumatoid arthritis.

Authors:  Hilde Berner Hammer; Lene Terslev
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

Review 5.  Management of persistent inflammatory large joint monoarthritis.

Authors:  Rachel Byng-Maddick; Lukshmy Jeyalingam; Andrew Keat
Journal:  Clin Rheumatol       Date:  2012-10-30       Impact factor: 2.980

Review 6.  Optimal dose of etanercept in the treatment of rheumatoid arthritis.

Authors:  Elizabeth Mary Curtis; Jonathan Lewis Marks
Journal:  Open Access Rheumatol       Date:  2014-03-24

7.  Ultrasound-guided intra-articular triamcinolone acetonide injection for treating refractory small joints arthritis of rheumatoid arthritis patients.

Authors:  Shaokun Wang; Xianbin Wang; Ying Liu; Xiaofeng Sun; Yanchun Tang
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

8.  Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5.

Authors:  Paolo Durigutto; Paolo Macor; Federica Ziller; Luca De Maso; Fabio Fischetti; Roberto Marzari; Daniele Sblattero; Francesco Tedesco
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

9.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-10-25       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.